A disintegrin and metalloproteinase 17 (ADAM17) is a metalloprotease that is overexpressed in many cancer types, including renal cancers. However, the regulatory mechanisms of ADAM17 in cancer development and progression are poorly understood. In the present work, we provide evidence using overexpression and inhibition of microRNA 145 (miR-145) that miR-145 negatively regulates ADAM17 expression. Furthermore, we show that ADAM17 negatively regulates miR-145 through tumor necrosis factor-α, resulting in a reciprocal negative feedback loop. In this study, the expression of ADAM17 and miR-145 correlated negatively in renal cancer tumor tissues and cell lines, suggesting an important regulatory mechanism. Additionally, we showed that the regulation of ADAM17 is partly involved in the effects of miR-145 on proliferation and migration, whereas no involvement in chemosensitivity was observed. Importantly, in the healthy kidney, miR-145 was detected in different cell types including tubular cells, which are considered the origin of renal cancer. In renal cancer cell lines, miR-145 expression was strongly suppressed by methylation. In summary, miR-145 is downregulated in renal cancer patients, which leads to the up-regulation of ADAM17 in renal cancer. Importantly, miR-145 and ADAM17 are regulated in a reciprocal negative feedback loop. Neoplasia (2013) 15, 218-230 Abbreviations: ADAM, A disintegrin and metalloproteinase; RCC, renal cell carcinoma; TNF, tumor necrosis factor Address all correspondence to: Kai Doberstein, MSc, Pharmazentrum Frankfurt/Zentrum für Arzneimittelforschung, Entwicklung und Sicherheit
Introduction
Renal cell carcinoma (RCC) originates from renal tubules and is the most common cancer of the kidney, accounting for 90% to 95% of all renal tumors in adults [1] . Importantly, 60% of all affected patients develop metastases. Only 10% of RCC patients with metastases survive longer than 5 years, whereas 80% of RCC patients with non-metastatic disease survive 5 years or longer [2] . Given the scarce number of therapeutic regimens, alternative approaches are urgently needed to prolong patient survival.
An interesting potential target molecule is the metalloprotease a disintegrin and metalloproteinase 17 (ADAM17), which is overexpressed in several types of cancer, including renal cancer [3] [4] [5] [6] [7] [8] [9] [10] [11] . ADAM17 was originally identified as the protease of the tumor necrosis factor-α (TNF-α), which is important during inflammation and for the cancer microenvironment [12, 13] .
In RCC, ADAM17 expression increases with the degree of malignancy and it is essential to form xenograft tumors [11, 14] . Importantly, more than 70 cellular substrates have been identified for ADAM17, including TNF-α, transforming growth factor-α, and epidermal growth factor receptor (EGFR) ligands [15] . Interestingly, the expression levels of members of the ADAM family can be regulated by small non-coding microRNAs (miRNAs) [16] [17] [18] . Furthermore, miRNAs were shown to have an important role in the regulation of gene networks, including those that are essential for cancer development [19] [20] [21] .
miRNA 145 (miR-145) plays a crucial role in the differentiation of smooth muscle cells (SMCs) [22] [23] [24] . miR-145 is downregulated in many tumors, including hematopoietic tumors and solid tumors of the breast, ovary, head and neck, prostate, skin, lung, bladder, and cervix [25] [26] [27] [28] . Furthermore, the ectopic expression of miR-145 in cancer cells led to a loss in cell viability and induced cell death [26, 29, 30] . It has been considered that the down-regulation of miR-145 is an early event in many cancers, suggesting an important role in several cancer-related pathways [31, 32] . A number of genes that are important in different cancer pathways have been identified and validated as target genes of miR-145, including plasminogen activator inhibitor-1 (PAI-1), octamer-binding transcription factor 4 (Oct-4), sex determining region Y (SRY)-box 2 (Sox-2), c-Myc, and p70S6K1 [33] [34] [35] [36] . miR-145 is downregulated by promoter hypermethylation in many cancers [37] [38] [39] . Additionally, the tumor suppressor gene p53, which is inactive in about 50% of all cancers, upregulates miR-145 expression, whereas, in contrast, the Ras oncogene represses miR-145 expression [37, 40] . It has been implicated by Gregersen et al . that ADAM17 may be a target of miR-145 [41] .
In this study, we identified miR-145 as an miRNA that is downregulated in the majority of renal cell cancers by methylation. Furthermore, we provide evidence that miR-145 decreases proliferation and invasion by directly targeting the 3′ untranslated region (3′UTR) of ADAM17 mRNA. Additionally, we show that ADAM17 negatively regulates miR-145 expression through TNF-α, leading to a reciprocal negative feedback loop. Importantly, we found a negative correlation of miR-145 and ADAM17 expression in renal cancer samples, suggesting that these molecules could be promising targets for further treatment approaches.
Materials and Methods

Substances and Antibodies
To detect ADAM17 protein expression, we used the polyclonal antibody from Santa Cruz Biotechnology (Heidelberg, Germany; sc-13973). A β-actin antibody from Sigma-Aldrich (Taufkirchen, Germany) was used as a loading control. The metalloprotease inhibitors TAPI-0 and TAPI-2 were obtained from Calbiochem (Darmstadt, Germany). Recombinant human TNF-α was purchased from Peprotech (London, United Kingdom). Phorbol 12-myristate 13-acetate (PMA) and 5-aza-2′-deoxycytidine (AZA) were obtained from Sigma (St Louis, MO) and cisplatin from Teva (Radebeul, Germany).
Cell Culture
The renal carcinoma cell line A498 was obtained from Dr K. Joehrer (Innsbruck Medical University, Innsbruck, Austria), whereas the renal carcinoma cell line Foehn was a kind gift from Prof. Altevogt (German Cancer Research Center, Heidelberg, Germany). The renal carcinoma cell lines RCC4 and 786-0 were obtained from Prof. Krek (ETH Zurich, Zürich, Switzerland). Protein isolation and Western blot analyses were performed as previously described [42] .
cDNA Synthesis and Polymerase Chain Reaction Analysis RNA from cultured cells was isolated using the RNA Easy Kit according to the manufacturer's protocol (Qiagen, Hilden, Germany). Equal amounts of total cellular RNA (1 μg) were reverse transcribed with random primer by the use of M-MuLV Reverse Transcriptase (Fermentas, St Leon-Rot, Germany). Transcribed cDNAs were used for polymerase chain reaction (PCR) with specific primers for ADAM17 (435 bp, 5′-GCATTCTCAAGTCTCCACAAG-3′ and 5′-CCTCATTCGGG-GCACATTCTG-3′), PAI-1 (183 bp, 5′-GAGGTGCCTCTCTCTG-CCCTCACCAACATT-3′ and 5′-AGCCTGAAACTGTCTGAACAT-GTCG-3′), c-Myc (478 bp, 5′-TACCCTCTCAACGACAGCAG-3′ and 5′-TCTTGACATTCTCCTCGGTG-3′), β-actin (234 bp, 5′-GGACTTCGAGCAAGAGATGG-3′ and 5′-AGCACTGTGTTGG-CGTACAG-3′), and pri-miR-145 (73 bp, 5′-TGGATTTGCCTCCT-TCCCA-3′ and 5′-TTGAACCCTCATCCT GTGAGCC-3′). The method described by Chen et al. was followed for stem-loop reverse transcription of mature miRNAs [43] . For miR-145, the stem-loop primer 5′-GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTG-GATACGACAGGGAT-3′ was used, and for U48, the stem-loop primer 5′-GTTGGCTCTGGTGCAGGGTCCGAGGT-ATTCGC-ACCAGAGCCAACGGTCAG-3′ was used. For miR-143, the commercially available primers from Exiqon (Vedbaek, Denmark) were used (#204190). The reverse transcribed product of miR-145 was then amplified by PCR with specific primers (5′-CGGCGTCCAGTTTT-CCCAGG-3′ and 5′-GTGCAGGGTCCGAGGT-3′, and for U48, 5′-CGACGAGTGATGATGAC-3′ and 5′-GTGCAGGGTCCG-AGGT-3′).
Real-time PCR
Real-time PCR was performed as described in the protocol from the Absolute Blue QPCR SYBR Green Low ROX Kit (Thermo Scientific, Hilden, Germany). The same primers as for the conventional PCR were also used for the real-time PCR. The C T values of analyzed RNA levels were normalized to the C T values of β-actin for mRNA and for miR-145 to U48 (housekeeping miRNA) within the same sample.
Luciferase Constructs
To construct luciferase reporter plasmids, we inserted various target fragments into multiple cloning site (MCS; XhoI and NotI) downstream of the Renilla luciferase reporter gene in the psiCHECK-2 promoter vector (Promega, Madison, WI). 5′ Modified primers carrying restriction sites for either XhoI or NotI were used (sequence printed in bold). The sequence from 3075 to 3082 (5′-AACTGGAA-3′) in the human ADAM17 mRNA (NM_003183.4) was termed miR-145 binding site.
The 761-nt fragment of the ADAM17 3′UTR (2613-3373, NM_ 003183.4) was generated using the following primer set: forward, 5′-atactcgagACTGCAGCGTCAGAATCGTGTTGA-3′ and reverse, 5′-atagcggccgcCCCAGCAAATCAGGGCCCTAAACA-3′.
Site-directed mutagenesis of the miR-145 binding site in the ADAM17 3′UTR was carried out with the QuickChange Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA), using the following primers: 5′-GAGGCATTTGGCATTTATTTGTGATGACAgcaga-aATAGTTTTTTT-3′ and 5′-AAAAAAACTATttctgcTGTCATCAC-AAATAAATGCCAAATGCCTC-3′.
A fragment containing the perfect matching sequence with the mature miR-145, 5′-atactcgagAGGGATTCCTGGGAAAACTGGACgcggccgcata-3′ (the matching sequence is underlined), was cloned (psiCHECK-2-p145). All constructs were sequenced.
Luciferase Assay
Human embryonic kidney 293 (HEK293) cells (3 × 10 5 per six-well plate) were transfected using the Lipofectamine 2000 transfection reagent (Invitrogen, Carlsbad, CA). Control RNA (20 nM) or miR-145 was co-transfected with 400 ng of appropriate plasmids and lysed for luciferase assay 24 hours after transfection. Luciferase assays were performed using a Dual-Luciferase Reporter Assay System (Promega) according to the manufacturer's protocol. Firefly luciferase was used for normalization.
Oligonucleotide Transfection
The following siRNA duplexes (MWG Biotech AG, Ebersberg, Germany) were used for down-regulation of the corresponding protein expression: ADAM17-siRNA, 5′-GAGAAGCUUGAUUCUUUG-CTT-3′. The transfection of miR-145 mimic (10 nM), miR-145 inhibitor (10 nM; both Qiagen), and miR-143 locked nucleic acid (LNA; Exiqon) inhibitors was performed in the same manner. As negative controls, unspecific AllStars negative control RNA from Qiagen or LNA control from Exiqon was used. Twenty-four hours before transfection, 0.4 × 10 5 cells were seeded in six-well plates. Transfection of siRNA was carried out using Oligofectamine (Invitrogen, Karlsruhe, Germany) together with 10 nM siRNA duplex per well as previously described [44] .
Immunohistochemistry and In Situ Hybridization
The in situ hybridization was performed with a 3′ and 5′ double DIGlabeled LNA miR-145 probe (Exiqon). The hybridization protocol has been described in detail by Jorgensen et al. [45] . After miR-145 staining, development and immunohistochemistry staining, starting with the first antibody, was continued with the same slide. Immunohistochemistry has been previously described [46] .
Cell Cycle Analysis
Seventy-two hours after transfection, cells were trypsinized, washed in phosphate-buffered saline, and fixed with 70% ethanol at −20°C. After centrifugation, cells were incubated in hypotonic solution containing 50 μg/ml propidium iodide, 0.1% sodium citrate, 0.1% Triton X-100, and 20 μg/ml DNase-free RNaseA for 30 minutes at 37°C. Finally, cells were analyzed using flow cytometry in a linear mode. Each assay was performed in triplicates and repeated at least three times.
Patient Material
Tumor specimens and adjacent normal kidney tissues were collected from a total of 15 patients undergoing nephrectomy for RCC. All specimens were obtained on the basis of their availability for research purpose and under a protocol approved by the local medical ethics committee of Goethe University Frankfurt. Written consent was obtained from the patients in the study.
Cell Invasion Assay
The cell migration assay has been described earlier [47] .
Proliferation Assay
The proliferation assay has been previously described [48] .
Statistical Analysis
If not otherwise indicated in the figure legends, Student's t test was used for statistical analyses.
Results
miR-145 Downregulates ADAM17 Protein Expression in Renal Cancer Cell Lines
The computational algorithms TargetScan, PicTar, and miRANDA were used to identify miRNAs that could potentially regulate ADAM17 expression [49] [50] [51] . These programs search for miRNAs that target evolutionary conserved sequences in the 3′UTR of the mRNA of the molecule of interest. miR-145 was one of two miRNAs predicted by all three programs to bind to the ADAM17 3′UTR ( Figure 1, A and  B) . Importantly, it was shown in three microarray studies by miRNA profiling of renal cancer patients that miR-145 is regulated in cancer tissue [52] [53] [54] .
Next, we investigated the miR-145 levels in a primary renal tubular cell line and in four renal cancer cell lines. The primary renal tubular cell line HRCepiC expressed higher levels of miR-145 than the renal cancer cell lines RCC4, 786-0, A498, and Foehn ( Figure 1C ). In contrast, the tubular cell line HRCepiC expressed the lowest amounts of ADAM17 protein and mRNA when compared to renal cancer cell lines ( Figure 1 , D and E).
To analyze the miR-145 and ADAM17 expression in renal cancer patients, we isolated renal cell cancer and corresponding normal kidney RNA from 15 patients and analyzed the expression levels by real-time PCR ( Figure 1F ). Interestingly, in only one tumor specimen, miR-145 was moderately upregulated (+3.8); in four renal cancer tissues, it was virtually unchanged (+1.4 to −1.1), while in 10 renal cancer tissues, it was downregulated, ranging from 1.7-fold to more than 65-fold down-regulation, with an overall average of 8.9-fold down-regulation (P < 10 −4 ). In contrast, only one patient displayed a decrease in ADAM17 expression (1.9), whereas six displayed almost no change (+1.2 to −1.4) and eight showed an up-regulation (+1.6 to +5.8) in tumor tissue compared to normal tissue with an overall average of 1.2-fold increase (P < .05).
The expression of miR-145 was further plotted versus the mRNA expression of ADAM17 for every individual patient ( Figure 1G ). Interestingly, all patient values were plotted in a small corridor, with the exception of patient number 218 that displayed the strongest decrease in miR-145 (−65.2) and ADAM17 (−1.9) expression. When analyzing the values in the marked corridor (14 of 15 patients), miR-145 and ADAM17 showed a significant negative correlation (K = −0.67), providing evidence for the regulation of ADAM17 by miR-145 in vivo. In contrast, when analyzing the known genes c-Myc and PAI-1, which have been described as miR-145 target genes, we could not find a correlation ( Figure 1 , H and I).
To determine the localization of miR-145 in normal human renal tissue, we performed in situ hybridization with miR-145-specific probes, followed by immunohistochemical staining with an antibody against aquaporin-1, which is known as a marker of proximal tubules [55] . miR-145 was strongly expressed in SMCs of blood vessels and inside the glomerulus (Figure 1 , I, K , and N ). Additionally, tubules adjacent to glomeruli and small tubules displayed distinct miR-145 expression ( Figure 1 , M and N ).
miR-145 Regulates ADAM17 Expression through Direct Binding to the 3′UTR
Next, we evaluated the ability to inhibit or overexpress miR-145 using a commercial miR-145 inhibitor or mimic in the renal cancer cell lines A498 and Foehn. The cells were transfected with miR-145 inhibitor, the miR-145 mimic, or a control RNA. Transfection efficiency was measured by reverse transcription-PCR, which demonstrated that the miR-145 levels were efficiently changed ( Figure W1, A and B) . The reduction of miR-145 after inhibitor transfection indicates a degradation of mature miR-145 [56] . Importantly, in A498 and Foehn cells, the transfection of miR-145 mimic led to a strong reduction in ADAM17 protein expression, whereas the transfection with the miR-145 inhibitor increased ADAM17 protein expression in both cell lines ( Figure 2, A and B) .
To investigate whether miR-145 represses ADAM17 expression through direct binding on the ADAM17 3′UTR, we introduced the predicted miR-145 binding site into the 3′UTR of a luciferase reporter gene. We found that the transfection of HEK293 cells with miR-145 mimics reduced the luciferase activity significantly, whereas it had no effects on the mutated binding site ( Figure 2C ).
Taken together, we observed that miR-145 regulates the protein expression of ADAM17, which might be due to the direct interaction of miR-145 with the 3′UTR of ADAM17 mRNA.
Inhibition of miR-143 Reduces ADAM17 Expression in Renal Cancer Cells
Because miR-145 is transcribed in a cluster with miR-143, and both have been shown to work synergistically in several cell models, we analyzed the expression of miR-143 in our renal cancer cell model. When comparing different renal cancer cell lines, the A498 cell line had the highest, whereas Foehn cells had the lowest expression of miR-143 ( Figure 3A) . The transfection of the Foehn cells with miR-145 mimic leads to an increase in miR-143 levels, whereas in the A498 cells this leads to a decrease of miR-143 expression ( Figure 3 , B and C). Interestingly, when we transfected the A498 cells with an miR-143 inhibitor, it led to a decrease in miR-145 expression ( Figure 3D ). Surprisingly, the inhibition of miR-143 led to a reduction of ADAM17 protein expression but showed that miR-143 and miR-145 do not regulate ADAM17 synergistically ( Figure 3E ).
ADAM17 Is Involved in the Effects of miR-145 on Proliferation and Invasion
To assess the functional role of miR-145 in renal cancer cells, we transfected Foehn cells with the miR-145 inhibitor and proliferation was measured ( Figure 4A ). Interestingly, miR-145 inhibitor-treated cells proliferated faster than control cells, whereas transfection with Figure 1. (continued) .
the miR-145 mimic led to a significant reduction in cell proliferation ( Figure 4B) . A cell cycle analysis was performed to determine the role of miR-145 in the regulation of the cell cycle. Importantly, the miR-145 mimic led to a 65% increase in cells in sub-G 1 /G 0 , whereas the miR-145 inhibitor led to a significant reduction of cells in sub-G 1 /G 0 ( Figure 4C ) . The sub-G 1 /G 0 phase represents cells that harbor a fragmented nucleus, which is an early event during apoptosis in which endonucleases start to cleave the genomic DNA [57] .
We further observed that the amount of S-phase cells decreased after miR-145 transfection and increased significantly after transfection with miR-145 inhibitor. Because the S-phase represents cells during genome duplication, it can be used as an indirect measurement of cell proliferation ( Figure 4C ). Similar effects on cell cycle and proliferation were observed in A498 cells ( Figure W2, A and B) .
The role of miR-145 was further analyzed in RCC4 cells, which expressed the highest miR-145 levels. The transfection of RCC4 cells with miR-145 mimic and inhibitor was assessed by real-time PCR ( Figure W1C ). Interestingly, in contrast to Foehn and A498 cells, the transfection of miR-145 did not induce apoptosis in RCC4 cells ( Figure 4D ). Although no direct influence on cell death was observed, the role of miR-145 in the resistance of renal cancer cells against the chemotherapeutic reagent cisplatin (CDDP) was further investigated. Transfection of miR-145 mimic significantly increased the amount of apoptotic cells after the treatment with CDDP (Figure 4D) . In contrast, the transfection with miR-145 inhibitor significantly reduced the number of cells in sub-G 1 /G 0 CDDP treated and untreated ( Figure 4E ).
To investigate whether ADAM17 is involved in miR-145-regulated proliferation, RCC4 cells were transfected with miR-145 inhibitor and additionally with ADAM17 siRNA. The induced proliferation rate after transfection with miR-145 inhibitor was partially inhibited when ADAM17 was also silenced ( Figure 4F) . Similarly, increased invasion after miR-145 inhibition was partly abrogated by the down-regulation of ADAM17 ( Figure 4G ). In contrast, miR-145 inhibitor together with ADAM17 siRNA did not change the chemoresistance of RCC4 cells against CDDP when compared to the transfection of miR-145 inhibitor alone ( Figure 4H ). The down-regulation of ADAM17 by The densitometrical analysis of the ADAM17 expression to β-actin is additionally depicted (n = 3). (C) Luciferase assays with reporter constructs containing either ADAM17 3′UTR with the predicted miR-145 binding site or the mutated binding site. Furthermore, a reporter construct carrying the complement sequence of the mature form of miR-145 was transfected as positive control. The Renilla luciferase activity for each construct was normalized with firefly luciferase activities. Fold change = (S renilla /S firefly )/(C renilla /C firefly ). miR-145 in RCC4 cells was confirmed by Western blot analysis ( Figure 3I ). ADAM17 siRNA alone had no effect on proliferation or invasion in RCC4 cells ( Figure W3, A and B) .
ADAM17 Regulates miR-145 in a Reciprocal Negative Feedback Loop
Because it has been demonstrated that various miRNAs, including miR-145, can be regulated by positive or negative feedback loops, we analyzed whether also ADAM17 is able to regulate miR-145 expression [30, 58, 59] .
Importantly, the down-regulation of ADAM17 led to a seven-fold induction of miR-145 expression ( Figure 5A ). One of the most prominent substrates of ADAM17 is TNF-α. To analyze whether the increase of miR-145 expression was mediated through the reduced cleavage of TNF-α, we treated the cells with recombinant TNF-α for 1 day, 48 hours after siRNA transfection. Importantly, TNF-α reduced the expression of miR-145 in the control transfected cells to about 40% ( Figure 5A ). In contrast, the seven-fold induction of miR-145 expression after ADAM17 down-regulation was abrogated by the addition of recombinant TNF-α ( Figure 5A ). These results suggest that the reduced cleavage of TNF-α after ADAM17 down-regulation leads subsequently to the up-regulation of miR-145.
To substantiate this hypothesis, we treated the cells with the metalloprotease inhibitor TAPI-2 or the ADAM17-specific inhibitor TAPI-0, and miR-145 expression was assessed. Importantly, TAPI-0 and TAPI-2 increased the miR-145 expression about two-fold ( Figure 5B ). In contrast, TNF-α and PMA stimulation, which activates the shedding of ADAM17 substrates, lead to the reduction of miR-145 expression. Interestingly, when analyzing both the miR-145 and ADAM17 expression after the treatment with TNF-α, the ADAM17 expression increases five-fold in contrast to miR-145 expression ( Figure 5C ). Therefore, our data suggest that the soluble factors cleaved by ADAM17 could be major regulators of miR-145 expression. The regulation of miR-145 by ADAM17 was further validated in Foehn cells ( Figure 5D ).
miR-145 Is Downregulated by Promoter Methylation
Because it is known from prostate cancer that miR-145 is downregulated by methylation, we examined whether methylation could also regulate miR-145 expression in renal cancer cells [37] . To test this hypothesis, we treated the cell lines A498, RCC4, and Foehn with AZA for 4 days. AZA leads to the demethylation of the DNA by inhibiting the DNA methyltransferase. AZA treatment resulted in an approximately 10-fold increase of mature miR-145 in A498 cells and a more than 40-fold increase in RCC4 and Foehn cells ( Figure 6A ). Because the increase should be reflected by an increase of the primary transcript, we measured the pri-miR-145, which shows no difference in A498 cells but a three-fold up-regulation in RCC4 and a six-fold up-regulation in Foehn cells ( Figure 6B ). In contrast, mature miR-143 expression, which is transcribed in a cluster with miR-145, showed no change in these cell lines ( Figure 6C) .
To determine whether the increase of miR-145 after demethylation regulates also ADAM17 expression, we measured ADAM17 protein expression after AZA treatment. In line with the previous results, all tested renal cancer cell lines displayed a reduced ADAM17 expression after AZA treatment ( Figures 6D and 7) .
Discussion
RCC is characterized by its resistance to current standard therapies [60] . Despite the rapid progress in the understanding of the molecular mechanisms of RCC, new treatment strategies are urgently needed.
In this context, ADAM metalloproteases are a promising family of proteins that are upregulated in several cancers [61] . miRNAs have been shown to be involved in the regulation of members of the ADAM family [16] [17] [18] . Furthermore, it has been demonstrated that the non-coding miRNAs have a versatile role for the regulation of genes during cancer development [62] . In the present study, miR-145 was identified as an miRNA that negatively regulates ADAM17. The binding was predicted by three different computational algorithms, providing a high probability that miR-145 would also regulate . Forty-eight hours after transfection, 10 μg/ml cisplatin (CDDP) was added to the cells for 24 hours. Cells were harvested and measured by cell cycle analysis as described in Materials and Methods section. The percentage of cells in the sub-G 1 /G 0 (apoptosis), G 1 (haploid genome), S (DNA synthesis), or G 2 (diploid genome) phase is displayed in a graph (n = 3). (E) RCC4 cells were transfected with control RNA (ctrl RNA) or miR-145 inhibitor (miR-145 inh). Forty-eight hours after transfection, 10 μg/ml CDDP was added to the cells for 24 hours. Cells were harvested and measured by cell cycle analysis as described in Materials and Methods section. The percentage of cells in the sub-G 1 /G 0 (apoptosis), G 1 (haploid genome), S (DNA synthesis), or G 2 (diploid genome) phase is displayed (n = 3). (F) RCC4 cells were transfected with control RNA (ctrl RNA), miR-145 inhibitor (miR-145 inh), or miR-145 inhibitor with ADAM17 siRNA (miR-145 inh + A17si). Twenty-four hours after RNA transfection, anchorage-dependent cell growth was measured at the time points 24, 48, and 72 hours after RNA transfection using an MTT assay. (G) RCC4 cells were transfected with control RNA (ctrl RNA), miR-145 inhibitor (miR-145 inh), or ADAM17 siRNA together with miR-145 inhibitor (miR-145 inh + A17si). Invasion assay was performed using matrigelcoated transwell chambers. (H) RCC4 cells were transfected with control RNA (ctrl RNA), miR-145 inhibitor (miR-145 inh), or ADAM17 siRNA together with miR-145 inhibitor (miR-145 inh + A17si). The percentage of cells in the sub-G 1 /G 0 (apoptosis) phase is displayed in a graph. (I) RCC4 cells were transfected with control RNA (ctrl RNA), miR-145 inhibitor (miR-145 inh), or ADAM17 siRNA together with miR-145 inhibitor (miR-145 inh + A17si). Cell lysates were investigated by Western blot using antibodies against ADAM17 (A17) and β-actin as a loading control. The densitometrical analysis of the ADAM17 expression to β-actin is additionally depicted. *P < .05, **P < .01, and P < .001 are considered statistically significant. ns, not significant.
ADAM17 directly under physiological conditions. The binding has been additionally suggested by Gregersen et al. [41] . The regulation of ADAM17 by miR-145 was shown in different renal cancer cell lines by the transfection of miR-145 mimic as well as by inhibiting miR-145 expression. The overexpression of miR-145 led to massive reduction in ADAM17 protein expression, whereas the inhibition of miR-145 increased the amount of ADAM17, demonstrating the importance of miR-145 in the regulation of ADAM17. By performing mRNA reporter assay, we could show that miR-145 can directly bind to the predicted 3′UTR of ADAM17 mRNA.
The idea that miR-145 has also a role in the regulation of ADAM17 was supported by the finding that cancer cell lines have reduced miR-145 expression and increased ADAM17 expression when compared to renal tubular control cell line. Importantly, miR-145 is downregulated in many cancers, whereas different studies demonstrated that ADAM17 was upregulated in the same cancer types [3] [4] [5] [6] [7] [8] [9] [10] [11] [25] [26] [27] [28] . In this study, we could show that, in most renal cancer patients, miR-145 is downregulated, whereas ADAM17 is upregulated. Moreover, the analysis of RCC patients revealed a significantly negative correlation of ADAM17 and miR-145, indicating that both genes are tightly regulated. Interestingly, the patient that was not included in the correlation had the worst clinical outcome with the highest number of metastases. This patient expressed the lowest relative amount of ADAM17 and miR-145, which could indicate that at this late stage ADAM17 might be downregulated by factors independent of miR-145. In agreement with our results, the down-regulation of miR-145 has been considered as an early event in other cancers, which has an influence on several tumor-promoting pathways [31, 32] .
miR-145 has been shown to be expressed in vascular SMCs, playing an essential role for smooth muscle development [22] [23] [24] . Similarly, we could detect strong miR-145 expression in vascular SMCs of the kidney. Additionally, we observed miR-145 expression in glomeruli and renal tubules, where the predominantly smaller tubules were positive for miR-145. In addition to the glomeruli, the Bowman's capsule and adjacent tubules expressed miR-145. These data suggest a role for miR-145 in normal adult glomeruli and renal tubules.
Our findings that miR-145 reduces proliferation and induces apoptotic cell death in renal cancer cells are in agreement with the results in other cancer types [36, 58, 63] . It was further demonstrated that ADAM17 is partially involved in the effects of miR-145 on proliferation and invasion, suggesting a role of additional target genes. Particularly, the regulation of the p53 repressor MDM2 by miR-145 could play a major role for the changes in cell cycle, chemoresistance, and proliferation [58] . Additionally, it was shown that miR-145 targets P70S6K1, which is important for the activation of the phosphatidylinositide 3-kinases (PI3K)/Akt pathway, resulting in reduced tumor growth [36] .
We also demonstrated that not only miR-145 negatively regulates ADAM17 but ADAM17 also downregulates the miR-145 reciprocal negative feedback loop. Positive and negative feedback loops have been described for many miRNAs, including miR-145 [30, 58, 59] . Similarly to our work, Xu and colleagues observed a reciprocal negative feedback loop of miR-145 and Oct4, resulting either in pluripotent cells with low miR-145 expression or differentiated cells with high levels of miR-145 [35] .
Reciprocal negative and positive feedback loops are often associated with a cell type switch that leads to a long-lasting cellular response [64, 65] .
Importantly, we showed that this regulation is transmitted by cleaved substrates of ADAM17, like TNF-α. TNF-α levels are often increased in the tumor microenvironment by tumor cells and by stroma cells, leading to a more tumorigenic tumor and increased metastasis. It would be interesting to investigate whether inhibition of the ADAM17 cleavage by specific inhibitors could reduce the cleaved substrates in the microenvironment and increase the miR-145 expression in tumor cells in vivo, thus resulting in better treatment options. Similar to our results, up-regulation of miR-145 in many cancer types induces antitumor properties like sensitivity toward chemotherapeutic treatment [26, 29, 30] . Moreover, we demonstrated that miR-145 is downregulated by methylation, which is in agreement with studies in other cancer types [37] [38] [39] . The strong induction of miR-145 after the addition of the demethylation agent in three cell lines indicates a direct methylation of miR-145 and not a secondary effect through a secondary regulator. Interestingly, we observed an increase of mature miR-145 that was about 10 times higher than the amount of the primary transcript. It could be that the treatment with AZA also increases the processing of primary miR-145 to the mature form. In contrast, no strong differences in mature miR-143, which is transcribed as a cluster together with miR-145, were observed, and this might be due to differences in processing. to the down-regulation of ADAM17 expression. As a consequence, less substrates are released by ADAM17, leading to an even higher expression of miR-145. As a result, ADAM17 is weakly expressed, whereas the miR-145 expression is high. (B) miR-145 expression is suppressed in renal cancer cells by an initial event, like promoter methylation. This leads to an up-regulation of ADAM17 expression, resulting in an increase of ADAM17-mediated cleavage of substrates like TNF-α. The released substrates then further suppress the expression of miR-145, leading to a reciprocal negative feedback loop. As a result, ADAM17 expression is elevated in renal cancer patients, whereas miR-145 is downregulated.
In the future, it would be important to analyze the methyla status of renal cancer patients. Given that, demethylation agents could be an important treatment option to increase miR-145 expression in renal cancer cells and thus sensitize renal cancer cells for therapy.
In summary, the data of the present work demonstrated that miR-145 is a tumor-suppressive miRNA in RCC that regulates the metalloprotease ADAM17. It could be a novel treatment strategy to increase the miR-145 expression by demethylation or by inhibiting the ADAM17 cleavage in renal cancer patients. Figure W2 . (A) A498 cells were transfected with control RNA (ctrl RNA) or miR-145 mimic (miR-145). Twenty-four hours after RNA transfection, anchorage-dependent cell growth was measured at the time points 24, 48, and 72 hours after siRNA transfection using an MTT assay (n = 3). (B) A498 cells were transfected with control RNA (ctrl RNA) or miR-145 mimic (miR-145). Cell cycle analysis was performed as described in Materials and Methods section. The percentages of Foehn cells in the sub-G 1 /G 0 (apoptosis), G 1 (haploid genome), S (DNA synthesis), or G 2 (diploid genome) phase are depicted (n = 3). **P < .01 and ***P < .001 are considered statistically significant. ns, not significant. Figure W3 . (A) RCC4 cells were transfected with control RNA (ctrl RNA) or ADAM17 siRNA (A17-siRNA). Twenty-four hours after RNA transfection, anchorage-dependent cell growth was measured at the time points 24, 48, and 72 hours after RNA transfection using an MTT assay. (B) RCC4 cells were transfected with control RNA (ctrl RNA) or ADAM17 siRNA (A17-siRNA). Invasion assay was performed using matrigel-coated transwell chambers.
